<p><em>哈勒博士加入以领导基于 Flagship 创新生物平台和新型模式创建新药物的工作</em></p>
<p>, /PRNewswire/ -- Flagship Pioneering，一家科学创新引擎，今天宣布任命玛丽·贝丝·哈勒（Mary Beth Harler）医学博士为 Pioneering Medicines 的总裁，这是 Flagship 内部的药物发现和开发单位。哈勒博士在生物技术和全球制药行业拥有超过二十年的高级领导经验，涵盖临床开发、组织建设和企业战略。</p>
<p>在这个角色中，哈勒博士将领导加速创造新型治疗药物的工作，并最大化 Flagship 首创生物平台的患者影响和价值。她将与 Flagship 创办的公司和领导者密切合作，以及通过公司的创新供应链合作伙伴关系与外部合作者合作。哈勒博士将向 Flagship Pioneering 的管理合伙人保罗·比昂迪（Paul Biondi）汇报，他将担任 Pioneering Medicines 监督委员会的主席。</p>
<p>比昂迪表示：“我们非常高兴欢迎玛丽·贝丝担任 Pioneering Medicines 的总裁。” 他说：“她结合了世界级的制药研发专业知识，包括对关键药物批准的责任，以及在多个治疗领域和模式中开发和交付项目的经验，拥有在生物技术组织扩展方面的创业经验。她在推进复杂投资组合和协调科学、战略与执行方面的能力，将在 Pioneering Medicines 进入下一个增长和影响阶段时发挥重要作用。”</p>
<p>最近，哈勒博士担任 IGM Biosciences 的首席执行官，在那里她领导了对公司投资组合的全面科学和战略重新评估，重组了运营，并建立了高效的执行团队和文化。在加入 IGM 之前，她在百时美施贵宝（Bristol Myers Squibb）工作了十多年，最终担任高级副总裁、免疫学和纤维化开发负责人，负责监督免疫学、纤维化和罕见疾病领域的 10-12 个资产的后期投资组合。</p>
<p>哈勒博士表示：“我很荣幸能加入 Flagship Pioneering，领导 Pioneering Medicines 这一独特角色。” 她说：“将突破性的生物平台转化为多个未满足需求领域的药物的机会非常令人兴奋。我期待与更广泛的 Flagship 生态系统合作，推动新一代变革性疗法的发展，为患者带来福音。”</p>
<p>哈勒博士在马歇尔大学医学院获得医学学位，并在布朗大学完成外科培训，同时担任普通外科的临床讲师。</p>
<p><strong>关于 Pioneering Medicines</strong></p>
<p>Pioneering Medicines 是 Flagship Pioneering 的内部药物开发单位，致力于构思和开发广泛的改变患者生活的治疗方案，基于 Flagship 的创新平台。Pioneering Medicines 结合其团队的药物开发专业知识与 Flagship 多个科学平台的力量，探索和识别新的产品概念，然后与 Flagship 的生物平台公司共同推进。在 Flagship 的创新供应链合作伙伴关系中，Pioneering Medicines 与外部合作者合作，应用其独特的方法来满足合作伙伴的研发优先事项。这些合作伙伴关系是高度共创的战略联盟，通过将合作伙伴汇聚在药物发现、开发和生产的全范围内，加速治疗创新。</p>
<p><strong>关于 Flagship Pioneering</strong></p>
<p>Flagship Pioneering 发明并建立平台公司，每个公司都有潜力开发多种产品，改变人类健康、可持续性等领域。自 2000 年成立以来，Flagship 已创办并培育了 100 多项科学事业，截至 2024 年 7 月最新融资时，其管理的资产总额达到 140 亿美元。目前的 Flagship 生态系统包括 40 多家公司，其中包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
<p>联系方式: [email protected]</p>
<p>来源：Flagship Pioneering</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE3Jk5ld3NJdGVtSWQ9TkU3NTkwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTcxMTMxUFJfTkVXU19VU1BSX19fX19ORTc1OTA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE3Jk5ld3NJdGVtSWQ9TkU3NTkwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTcxMTMxUFJfTkVXU19VU1BSX19fX19ORTc1OTA0"/></p>

IGMS

百时美施贵宝

<p>Flagship Pioneering 任命 Dr. Mary Beth Harler 为其药物发现部门 Pioneering Medicines 的总裁。Harler 博士在生物技术和制药领域拥有超过 20 年的经验，曾担任 IGM Biosciences 的首席执行官，并在百时美施贵宝担任高级职务。她将领导从 Flagship 的创新生物平台开发新型治疗药物的工作，与内部团队和外部合作伙伴合作。Harler 博士对将开创性的生物平台转化为满足医疗需求的药物表示兴奋</p>

<p><em>Dr. Harler Joins to Lead Effort to Create New Medicines Built from Flagship's Innovative Bioplatforms and Novel Modalities</em></p>
<div class="lb-trans"><p><em>哈勒博士加入以领导基于 Flagship 创新生物平台和新型模式创建新药物的工作</em></p>
</div><p>, /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for platforms and products, today announced the appointment of Mary Beth Harler, M.D., as President of Pioneering Medicines, Flagship's in-house drug discovery and development unit. Dr. Harler comes to Flagship with more than two decades of senior leadership experience across the biotechnology and global pharmaceutical industries, spanning clinical development, organizational building, and corporate strategy.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Flagship Pioneering，一家科学创新引擎，今天宣布任命玛丽·贝丝·哈勒（Mary Beth Harler）医学博士为 Pioneering Medicines 的总裁，这是 Flagship 内部的药物发现和开发单位。哈勒博士在生物技术和全球制药行业拥有超过二十年的高级领导经验，涵盖临床开发、组织建设和企业战略。</p>
</div><p>In this role, Dr. Harler will lead efforts to accelerate the creation of novel therapeutics and maximize the patient impact and value of Flagship's first-in-category bioplatforms. She will work closely with Flagship-founded companies and leaders, as well as external collaborators through the company's Innovation Supply Chain partnerships. Dr. Harler will report to Paul Biondi, Managing Partner at Flagship Pioneering, who will chair the Pioneering Medicines Oversight Board.</p>
<div class="lb-trans"><p>在这个角色中，哈勒博士将领导加速创造新型治疗药物的工作，并最大化 Flagship 首创生物平台的患者影响和价值。她将与 Flagship 创办的公司和领导者密切合作，以及通过公司的创新供应链合作伙伴关系与外部合作者合作。哈勒博士将向 Flagship Pioneering 的管理合伙人保罗·比昂迪（Paul Biondi）汇报，他将担任 Pioneering Medicines 监督委员会的主席。</p>
</div><p>&#34;We are thrilled to welcome Mary Beth as President of Pioneering Medicines,&#34; said Biondi. &#34;She combines world-class pharma R&amp;D expertise, including responsibility for key drug approvals and experience developing and delivering programs across therapeutic areas and modalities, with entrepreneurial experience in scaling biotech organizations. Her proven ability to advance complex portfolios and align science, strategy, and execution will be invaluable as Pioneering Medicines enters its next phase of growth and impact.&#34;</p>
<div class="lb-trans"><p>比昂迪表示：“我们非常高兴欢迎玛丽·贝丝担任 Pioneering Medicines 的总裁。” 他说：“她结合了世界级的制药研发专业知识，包括对关键药物批准的责任，以及在多个治疗领域和模式中开发和交付项目的经验，拥有在生物技术组织扩展方面的创业经验。她在推进复杂投资组合和协调科学、战略与执行方面的能力，将在 Pioneering Medicines 进入下一个增长和影响阶段时发挥重要作用。”</p>
</div><p>Most recently, Dr. Harler served as Chief Executive Officer of IGM Biosciences, where she led a comprehensive scientific and strategic re-evaluation of the company's portfolio, restructured operations, and established a high-performing executive team and culture. Before joining IGM, she spent more than a decade at Bristol Myers Squibb, ultimately serving as Senior Vice President, Head of Immunology and Fibrosis Development, where she oversaw a late-stage portfolio of 10–12 assets across immunology, fibrosis, and rare diseases.</p>
<div class="lb-trans"><p>最近，哈勒博士担任 IGM Biosciences 的首席执行官，在那里她领导了对公司投资组合的全面科学和战略重新评估，重组了运营，并建立了高效的执行团队和文化。在加入 IGM 之前，她在百时美施贵宝（Bristol Myers Squibb）工作了十多年，最终担任高级副总裁、免疫学和纤维化开发负责人，负责监督免疫学、纤维化和罕见疾病领域的 10-12 个资产的后期投资组合。</p>
</div><p>&#34;I am honored to join Flagship Pioneering to lead Pioneering Medicines in this unique role,&#34; said Dr. Harler. &#34;The opportunity to transform groundbreaking bioplatforms into medicines across multiple areas of unmet need is very exciting. I look forward to working with the broader Flagship ecosystem to advance a new generation of transformative therapies for patients.&#34;</p>
<div class="lb-trans"><p>哈勒博士表示：“我很荣幸能加入 Flagship Pioneering，领导 Pioneering Medicines 这一独特角色。” 她说：“将突破性的生物平台转化为多个未满足需求领域的药物的机会非常令人兴奋。我期待与更广泛的 Flagship 生态系统合作，推动新一代变革性疗法的发展，为患者带来福音。”</p>
</div><p>Dr. Harler earned her medical degree from Marshall University School of Medicine and completed surgical training at Brown University, where she also held a faculty appointment as Clinical Instructor of General Surgery.</p>
<div class="lb-trans"><p>哈勒博士在马歇尔大学医学院获得医学学位，并在布朗大学完成外科培训，同时担任普通外科的临床讲师。</p>
</div><p><strong>About Pioneering Medicines</strong></p>
<div class="lb-trans"><p><strong>关于 Pioneering Medicines</strong></p>
</div><p>Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Within Flagship's Innovation Supply Chain partnerships, Pioneering Medicines works with external collaborators to apply its unique approach to partners' R&amp;D priorities. These partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production.</p>
<div class="lb-trans"><p>Pioneering Medicines 是 Flagship Pioneering 的内部药物开发单位，致力于构思和开发广泛的改变患者生活的治疗方案，基于 Flagship 的创新平台。Pioneering Medicines 结合其团队的药物开发专业知识与 Flagship 多个科学平台的力量，探索和识别新的产品概念，然后与 Flagship 的生物平台公司共同推进。在 Flagship 的创新供应链合作伙伴关系中，Pioneering Medicines 与外部合作者合作，应用其独特的方法来满足合作伙伴的研发优先事项。这些合作伙伴关系是高度共创的战略联盟，通过将合作伙伴汇聚在药物发现、开发和生产的全范围内，加速治疗创新。</p>
</div><p><strong>About Flagship Pioneering</strong></p>
<div class="lb-trans"><p><strong>关于 Flagship Pioneering</strong></p>
</div><p>Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of current assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health.</p>
<div class="lb-trans"><p>Flagship Pioneering 发明并建立平台公司，每个公司都有潜力开发多种产品，改变人类健康、可持续性等领域。自 2000 年成立以来，Flagship 已创办并培育了 100 多项科学事业，截至 2024 年 7 月最新融资时，其管理的资产总额达到 140 亿美元。目前的 Flagship 生态系统包括 40 多家公司，其中包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
</div><p>CONTACT: [email protected]</p>
<div class="lb-trans"><p>联系方式: [email protected]</p>
</div><p>SOURCE Flagship Pioneering</p>
<div class="lb-trans"><p>来源：Flagship Pioneering</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE3Jk5ld3NJdGVtSWQ9TkU3NTkwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTcxMTMxUFJfTkVXU19VU1BSX19fX19ORTc1OTA0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NE75904&amp;Transmission_Id=202509171131PR_NEWS_USPR_____NE75904&amp;DateId=20250917"/></p>

旗舰开创公司任命 Mary Beth Harler 为开创药物部门总裁